Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
← catalyst calendarSponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
10actual
Sites
16
Countries
Belgium, Canada, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-22 | actual | When the study began enrolling |
| Primary completion | 2026-02-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-27 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Osteosarcoma
- Osteosarcoma in Children
- Osteosarcoma in Adolescents and Young Adults
Interventions
- Drug: Cabozantinib
- Other: Best Supportive Care (BSC)
- Other: Best Supportive Care (BSC)
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS) assessed by Blinded Independent Radiology Committee (BIRC)
measured From randomization until disease progression or death from any cause, whichever occurs first (approximately 34 months).
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed